Important early dates in the Covid-19 pandemic

- 30 Dec 2019: First notice of pneumonia cases in Wuhan
- 9 Jan 2020: Cause identified: a novel coronavirus
- 3 Feb 2020: Deaths worldwide pass 1,000
- 7 March 2020: Worldwide case count reaches 100,000
- 2 April 2020: Worldwide case count passes 1 million
- 10 April 2020: Worldwide deaths pass 100,000
- 28 Sept 2020: Worldwide deaths reach 1 million
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen*, Min Zhou*, Xuan Dong*, Jieming Qu*, Fengyun Gong, Yang Han, Yang Qiu, Jingli Wang, Ying Liu, Yuan Wei, Jia’an Xia, Ting Yu, Xinxin Zhang, Li Zhang

Summary
Background In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia.

Methods In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020. Cases were confirmed by real-time RT-PCR and were analysed for epidemiological, demographic, clinical, and radiological features and laboratory data. Outcomes were followed up until Jan 25, 2020.

Most patients were given antibiotic treatment (table 2); 25 (25%) patients were treated with a single antibiotic and 45 (45%) patients were given combination therapy. The antibiotics used generally covered common pathogens and some atypical pathogens; when secondary bacterial infection occurred, medication was administered according to the results of bacterial culture and drug sensitivity. The antibiotics used were cephalosporins, quinolones, carbapenems, tigecycline against meticillin-resistant Staphylococcus aureus, linezolid, and antifungal drugs. The duration of antibiotic treatment was 3–17 days (median 5 days [IQR 3–7]). 19 (19%) patients were also treated with methylprednisolone sodium succinate, methylprednisolone, and dexamethasone for 3–15 days (median 5 [3–7]).

All patients were treated in isolation. 75 (76%) patients received antiviral treatment, including oseltamivir (75 mg every 12 h, orally), ganciclovir (0·25 g every 12 h, intravenously), and lopinavir and ritonavir tablets (500 mg twice daily, orally). The duration of antiviral treatment was 3–14 days (median 3 days [IQR 3–6]).
Global number of reported smallpox cases

Polio cases by world region, 1980 to 2016

Shown is the estimate of the total number of paralytic polio cases.

Source: WHO (2018) and Tebbens et al. (2011)

Note: These estimates are based on a model by Tebbens et al. (2011) that multiplies the reported number of cases with a correction factor based on the quality of each country’s surveillance system. After a country is certified polio-free, however, the reported polio cases are used.
Reported cases and deaths of measles in the USA (1921-2015)

Source: Our World in Data (2017)

https://ourworldindata.org/grapher/measles-cases-and-death
## Coronavirus Vaccine Tracker

**By Carl Zimmer, Jonathan Corum and Sui-Lee Wee**  Updated Feb. 25, 2021

<table>
<thead>
<tr>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>AUTHORIZED</th>
<th>APPROVED</th>
<th>ABANDONED</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>27</td>
<td>20</td>
<td>8</td>
<td>4</td>
<td>4</td>
</tr>
</tbody>
</table>

- Vaccines testing safety and dosage
- Vaccines in expanded safety trials
- Vaccines in large-scale efficacy tests
- Vaccines in early or limited use
- Vaccines approved for full use
- Vaccines abandoned after trials

Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing **71 vaccines** in clinical trials on humans, and 20 have reached the final stages of testing. At least 78 preclinical vaccines are under active investigation in animals.

Classical vaccines

Preclinical stage (18-30 months)

Phase I (dozens of volunteers ~30 months)

Phase II (hundreds of volunteers ~32 months)

Phase III (thousands of volunteers ~30 months)

Approval, Manufacture, Vaccination (12-24 months)

COVID-19 vaccines

Preclinical stage (0 months)

Phase I (dozens of volunteers ~ 6 months)

Phase II (hundreds of volunteers ~ 6 months)

Phase III (thousands of volunteers ~ 0 months)

Approval, Manufacture, Vaccination (billions of doses/individuals ~ 6 months)
COVID-19 vaccine doses administered per 100 people, Feb 26, 2021

Total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).